Leqembi Facing 15% Price Cut In Japan

Outcome Of CEA Process

 
• By Lisa Takagi
  
CEA discussion on Leqembi
Eisai's Alzheimer's drug Leqembi appears set for 15% price cut in Japan following cost-effectiveness review. (Shutterstock/AI-generated)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Health Technology Assessment

More from Japan